A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation

Trial Profile

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Enasidenib (Primary)
  • Indications Glioma; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Agios Pharmaceuticals; Celgene Corporation
  • Most Recent Events

    • 17 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Nov 2015 Data from this trial are expected to be presented at the 2015 American Society of Hematology annual meeting, according to a Celgene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top